Printer Friendly

Immune dysfunction and immunotherapy in heart disease.


Immune dysfunction and immunotherapy in heart disease.

Ed. by Ronald Ross Watson and Douglas F. Larson.

Blackwell Futura


308 pages




Heart failure (HF) affects some five million Americans. Since there are currently no FDA-approved therapeutics for diastolic HF and those for systolic disease are considered palliative, Watson and Larson (both affiliated with the Sarver Heart Center, College of Medicine, U. of Arizona, Tucson) are among those seeking to develop immunomodulatory therapeutics to treat HF. In 28 chapters, international immunologists discuss such aspects of the multifactoral pathophysiology of HF as the roles of ultraviolet radiation, T-lymphocytes, and pro-inflammatory cytokines in disease progression; experimental models and clinical trials targeting such inflammatory mediators; and immune dysfunction relating to oral pathogens and diseases such as diabetes. Dietary markers of HF and the anti-inflammatory actions of antioxidants are also considered.

([c]20082005 Book News, Inc., Portland, OR)
COPYRIGHT 2008 Book News, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:SciTech Book News
Article Type:Book Review
Date:Mar 1, 2008
Previous Article:Acute medicine; a practical guide to the management of medical emergencies, 4th ed.
Next Article:The Gale encyclopedia of diets; a guide to health and nutrition; 2v.

Related Articles
Lysine helped CFIDS sufferer gain control of his life.
Advances in cancer immunotherapy.
Immunoendocrinology in Health and Disease.
Epstein-Barr Virus (Infectious Disease and Therapy).
Melatonin; present and future.
Neuroimmunology research perspectives.
Dermatologic immunity.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters